Acumen Pharmaceuticals (ABOS) Share-based Compensation (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Share-based Compensation data on file, last reported at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 3182.19% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (down 66.83% YoY), and the FY2025 full-year result was $73000.0, down 99.24% from the prior year.
• Share-based Compensation rose to $2.4 million in Q1 2026, from -$4.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.3 million in Q3 2024 to a low of -$4.9 million in Q3 2025.
• A 5-year average of $1.5 million and a median of $2.4 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 403.15% in 2022 and jumped 3182.19% in 2026, its largest moves.
• Tracing ABOS's Share-based Compensation over 5 years: stood at $2.8 million in 2022, then soared by 117.29% to $6.1 million in 2023, then sank by 61.87% to $2.3 million in 2024, then sank by 309.09% to -$4.9 million in 2025, then jumped by 148.91% to $2.4 million in 2026.
• Business Quant data shows ABOS's Share-based Compensation at $2.4 million in Q1 2026, -$4.9 million in Q3 2025, and $4.9 million in Q2 2025.